Recent clinical trials of gene therapy for patients with thoracic cancers have shown that these treatments were well tolerated with minimal side effects and that we need to further enhance specificity as well as efficiency of gene transfer to target cancer cells. We previously reported that mycovere
Gene therapy for lung cancer
โ Scribed by Eric M. Toloza; Michael A. Morse; H. Kim Lyerly
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 218 KB
- Volume
- 99
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Lung cancer patients suffer a 15% overall survival despite advances in chemotherapy, radiation therapy, and surgery. This unacceptably low survival rate is due to the usual finding of advanced disease at diagnosis. However, multimodality strategies using conventional therapies only minimally improve survival rates even in early stages of lung cancer. Attempts to improve survival in advanced disease using various combinations of platinumโbased chemotherapy have demonstrated that no regimen is superior, suggesting a therapeutic plateau and the need for novel, more specific, and less toxic therapeutic strategies. Over the past three decades, the genetic etiology of cancer has been gradually delineated, albeit not yet completely. Understanding the molecular events that occur during the multistep process of bronchogenic carcinogenesis may make these tasks more surmountable. During these same three decades, techniques have been developed which allow transfer of functional genes into mammalian cells. For example, blockade of activated tumorโpromoting oncogenes or replacement of inactivated tumorโsuppressing or apoptosisโpromoting genes can be achieved by gene therapy. This article will discuss the therapeutic implications of these molecular changes associated with bronchogenic carcinomas and will then review the status of gene therapies for treatment of lung cancer. J. Cell. Biochem. ยฉ 2006 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
There is a growing interest in evaluating molecular markers as predictors of response to new generation of targeted cancer therapies. One of such areas is biological therapy targeting epidermal growth factor receptor gene (EGFR) in lung cancer. The testing of tumor tissue is focused on specific EGFR
## Abstract The presence of activating mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene has been attributed to a positive response to biological therapy of lung cancer by smallโmolecular tyrosine kinase inhibitors, gefitinib and erlotinib. Among the two most
## Abstract ## Background and Objective Endobronchial photodynamic therapy (PDT) is a minimally invasive technique for the palliation of major airway obstruction from lung cancer, and for the treatment of endobronchial microinvasive lung cancer. ## Study Design Results of reported clinical trial